Extra Sildenafil Before Exercise in Pulmonary Arterial Hypertension, Compared With Dextrose Candy
Tests extra sildenafil on top of usual treatment in adults with pulmonary arterial hypertension.
Plain-language title generated from the registry record
Registry title: The Effect of Additive On-Demand Sildenafil vs. Dextrose Candy on Maximum Exercise Capacity in Pulmonary Arterial Hypertension
Key facts
- Where
- Zurich, SwitzerlandSee the site
- Phase
- Phase 2/3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07824674, who can take part
Where in Switzerland
- University Hospital of Zurich, Department of PulmonologyZurich, SwitzerlandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Silvia Ulrich
- Trial code
- NCT07824674
- Record updated
- 4 November 2026
- Original description
The goal of this clinical study is to investigate whether the additional intake of sildenafil 20mg on top of standard medical treatment results in a benefit on maximum exercise workload (Wmax) in patients with pulmonary arterial hypertension (PAH).Read full original descriptionShow less
The Effect of Additive On-Demand Sildenafil vs. Dextrose Candy on Maximum Exercise Capacity in Pulmonary Arterial Hypertension: A Randomized, Cross-Over Trial.
The goal of this clinical study is to investigate whether the additional intake of sildenafil 20mg on top of standard medical treatment results in a benefit on maximum exercise workload (Wmax) in patients with pulmonary arterial hypertension (PAH).
Inclusion: Signed Informed consent; Age 18 - 80 years (both sexes); Pulmonary hypertension (PH) class I (PAH) previously diagnosed according to ESC/ERS 2022/2019 guidelines (mPAP ≥ 20 mmHg, PVR ≥ 2 WU, PAWP ≤ 15 mmHg) during diagnostic right-heart catheterization; Stable condition, on the same PH-medication for >4 weeks.
Exclusion: Other clinically significant concomitant disease states (e.g., severe renal or hepatic disease, unstable cardiovascular disease, etc.); Concurrent medication with:; Nitric oxide donors (molsidomine, nicrorandil, etc.); Soluble guanylate cyclase stimulators (riociguat); Potent CYP3A4 inhibitors (azoles, clarithromycin, protease inhibitors); Participation in another study with investigational drug with potential influence the study data within the 30 days preceding and during the present study; Moderate-to-severe chronic obstructive or restrictive pulmonary disease (FEV1 ≤ 60% predicted, FVC ≤ 60% predicted); History of anterior ischemic optic neuropathy or hereditary retinal disease; Known allergies or hypersensitivity to sildenafil 20mg (Revatio 20mg) or dextrose candy (Dextroenergy) including any of its components; Severe resting hypoxia (PaO2 <7.3 kPa); Women with known pregnancy or breast feeding.